文献速递妇科

SGLT2抑制剂联用孕激素与子宫内膜癌风险

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.
PubMed 文献 · Gynecol Oncol · 2026-07-02

回顾性队列研究基于TriNetX数据库,纳入486,837例因良性子宫病变或增生接受孕激素治疗的患者,其中7,605例联用SGLT2抑制剂。倾向评分匹配后随访2年,联用组子宫内膜癌风险(HR 0.43,95%CI 0.28-0.67)和子宫切除术风险(HR 0.51,95%CI 0.43-0.60)均显著低于单用孕激素组。

要点

  • 亚组及敏感性分析结果与主分析基本一致

核心结论

  • 在因良性子宫病变或增生接受孕激素治疗的患者中,联用SGLT2抑制剂与较低的子宫内膜癌和子宫切除术风险相关。

研究设计与样本

  • 回顾性队列研究,使用TriNetX真实世界临床数据库,纳入486,837例接受孕激素治疗的患者,其中7,605例(1.6%)联用SGLT2抑制剂,479,232例(98.4%)单用孕激素。
  • 经1:1倾向评分匹配后,每组各7,034例,随访2年。

主要发现

  • 随访2年,联用组子宫内膜癌发生29例(0.4%),单用组65例(0.9%)。
  • 联用SGLT2抑制剂与子宫内膜癌风险降低相关(HR 0.43;95%CI 0.28-0.67)。
  • 联用SGLT2抑制剂与后续子宫切除术风险降低相关(HR 0.51;95%CI 0.43-0.60)。
  • 亚组分析(按孕激素给药途径、子宫病理、年龄、BMI)及敏感性分析结果与主分析基本一致。

临床怎么用

  • 对于因良性子宫病变或增生接受孕激素治疗且合并SGLT2抑制剂使用指征的患者,联用可能降低子宫内膜癌和子宫切除术风险。
  • 该发现需前瞻性研究进一步验证适用性和潜在机制。

局限性

  • 回顾性观察性设计,可能存在残余混杂,尽管进行了倾向评分匹配和敏感性分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether concomitant sodium-glucose cotransporter 2 inhibitor (SGLT2i) and progestin therapy is associated with the risk of incident endometrial cancer (EC) and subsequent hysterectomy among patients with endometrial hyperplasia (EH) or benign uterine pathology. METHODS: We conducted a retrospective cohort study using the TriNetX real-world clinical database. Patients with EH, abnormal uterine bleeding, or other benign uterine pathology who received progestin therapy were identified and grouped by concomitant SGLT2i use. Propensity score matching (PSM) was performed to balance baseline characteristics between the SGLT2i + progestin and progestin-only groups. Primary outcomes were incident EC, subsequent hysterectomy, and a composite outcome of EC or hysterectomy. Subgroup analyses were performed by route of progestin administration, uterine pathology, age, and body mass index. Sensitivity analyses were conducted to address potential residual confounding. RESULTS: A total of 486,837 eligible patients were included, including 7605 (1.6%) in the SGLT2i + P group and 479,232 (98.4%) in the P-only group. After 1:1 PSM, 7034 patients remained in each group. During 2-years of follow-up, EC occurred in 29 patients (0.4%) in the SGLT2i + P group and 65 (0.9%) in the P-only group. Compared with progestin alone, SGLT2i + progestin was associated with lower risks of incident EC (HR, 0.43; 95% CI, 0.28-0.67) and subsequent hysterectomy (HR, 0.51; 95% CI, 0.43-0.60). Findings were generally consistent across subgroups and sensitivity analyses. CONCLUSIONS: Concomitant SGLT2i use was associated with lower risks of EC and hysterectomy among patients receiving progestin therapy for non-malignant uterine pathology. Further prospective evaluation is warranted to assess its applicability and underlying mechanisms.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yen TT, Lu CA, Hsieh TYJ, et al. Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia. Gynecol Oncol. 2026. PMID: 42385610. doi:10.1016/j.ygyno.2026.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。